Neurophyt (Co-CEOs Bin Jun-gil and Kim Dong-hyun), a company specializing in artificial intelligence (AI) for brain disease diagnosis and treatment, announced on the 20th that it has signed a supply agreement with the National University of Singapore (NUS) and Singapore General Hospital (SGH) to supply 'Neurophet SCALE PET', a quantitative analysis software for PET (positron emission tomography) images.
Through this agreement, Neurofit will supply software to the relevant institution, verify the clinical utility of its analysis technology based on brain MRI and PET image data, and pursue technology commercialization based on this data.
NeuroFit Scale Pet is software that quantitatively analyzes biomarkers labeled with radioactive tracers (PET tracers) using PET images and MRI. It analyzes a variety of biomarkers, including amyloid beta protein and tau protein, which are associated with Alzheimer's disease, as well as FDG and dopamine. It automatically calculates the Standardized Uptake Value Ratio (SUVR), which can be used for diagnosis and research.
The National University of Singapore ranked 8th in the 2025 QS World University Rankings, and Singapore General Hospital was ranked 1st in Asia and 11th in the world in the 2024 Newsweek World's Best Hospitals rankings.
Neurofit Co-CEO Bin Jun-gil said, “Supplying Neurofit technology to global research institutes and medical institutions is an important milestone in securing clinical reliability,” and added, “This supply will also accelerate our expansion into the Southeast Asian market.”
- See more related articles
You must be logged in to post a comment.